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BSTRACT
 
Background
 
The efficacy and safety of adding a
protease inhibitor to two nucleoside analogues to
treat human immunodeficiency virus type 1 (HIV-1)
infection are not clear. We compared treatment with
the protease inhibitor indinavir in addition to zidovu-
dine and lamivudine with treatment with the two nu-
cleosides alone in HIV-infected adults previously treat-
ed with zidovudine.
 
Methods
 
A total of 1156 patients not previously
treated with lamivudine or protease inhibitors were
stratified according to CD4 cell count (50 or fewer vs.
51 to 200 cells per cubic millimeter) and randomly
assigned to one of two daily regimens: 600 mg of zi-
dovudine and 300 mg of lamivudine, or that regimen
with 2400 mg of indinavir. Stavudine could be sub-
stituted for zidovudine. The primary end point was
the time to the development of the acquired immu-
nodeficiency syndrome (AIDS) or death. 
 
Results
 
The proportion of patients whose disease
progressed to AIDS or death was lower with indina-
vir, zidovudine (or stavudine), and lamivudine (6 per-
cent) than with zidovudine (or stavudine) and lami-
vudine alone (11 percent; estimated hazard ratio,
0.50; 95 percent confidence interval, 0.33 to 0.76;
P
 

 
0.001). Mortality in the two groups was 1.4 per-
cent and 3.1 percent, respectively (estimated hazard
ratio, 0.43; 95 percent confidence interval, 0.19 to
0.99; P
 

 
0.04). The effects of treatment were similar
in both CD4 cell strata. The responses of CD4 cells
and plasma HIV-1 RNA paralleled the clinical results.
 
Conclusions
 
Treatment with indinavir, zidovudine,
and lamivudine as compared with zidovudine and
lamivudine alone significantly slows the progression
of HIV-1 disease in patients with 200 CD4 cells or
fewer per cubic millimeter and prior exposure to zi-
dovudine. (N Engl J Med 1997;337:725-33.)
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ROGRESS in the field of antiretroviral ther-
apy for human immunodeficiency virus type
1 (HIV-1) infection has brought the end of
the zidovudine-monotherapy era,
 
1-3
 
 an im-
proved understanding of the pathogenesis of HIV-1
disease,
 
4-9
 
 demonstrations of the prognostic impor-
tance of plasma HIV-1 RNA quantification,
 
10-17
 
 and
the availability of increasingly potent therapeutic
agents. Much of this progress is linked to the intro-
duction of the HIV-protease inhibitors, drugs that
inhibit the processing of Gag and Gag–Pol polypro-
tein precursors and thus prevent the maturation of
virions.
 
18-20
 
 Trials of HIV-protease inhibitors have
shown beneficial effects on CD4 cell counts and plas-
ma HIV-1 RNA concentrations to a degree not pre-
viously described with approved reverse-transcriptase
inhibitors.
 
21-26
 
 The most notable findings have in-
volved three-drug combinations that include a po-
tent HIV-protease inhibitor and two nucleoside an-
P
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alogues. Specifically, when patients previously ex-
posed to zidovudine who had either 50 to 400 or
50 or fewer CD4 cells per cubic millimeter were
treated with indinavir, zidovudine, and lamivudine,
plasma HIV-1 RNA concentrations were suppressed
to less than 500 copies per milliliter in 85 percent
and 65 percent of patients, respectively.
 
24,25
 
 These
findings have raised the important question of the
clinical efficacy and safety of a three-drug regimen
containing indinavir. We addressed that issue in this
study.
 
METHODS
 
Study Design and Patients
 
The AIDS Clinical Trials Group 320 Study was a randomized,
double-blind, placebo-controlled trial that compared the three-
drug regimen of indinavir (Crixivan), open-label zidovudine
(Retrovir) or stavudine (Zerit), and lamivudine (Epivir) with the
two-drug regimen of zidovudine (or stavudine) and lamivudine
in HIV-infected patients who had no more than 200 CD4 cells
per cubic millimeter and at least three months of prior zidovudine
therapy. The randomization was stratified according to the CD4
cell count obtained at the time of screening (50 or fewer cells per
cubic millimeter as compared with 51 to 200 cells per cubic mil-
limeter). The study was designed to enroll 1750 patients, with 40
percent of them in the stratum with 50 or fewer CD4 cells per
cubic millimeter. The primary outcome measure in the assess-
ment of efficacy was the development of a new acquired immu-
nodeficiency syndrome (AIDS)–defining event (except when the
AIDS-defining event was the development of 
 
Pneumocystis carinii
 
pneumonia, in which case both new and recurrent events were ac-
cepted as outcome measures) or death; in the assessment of safe-
ty, the outcome measure was the occurrence of adverse events
(signs, symptoms, or laboratory abnormalities) defined as severe
or worse according to the grading scheme of the AIDS Clinical
Trials Group.
 
27
 
 The secondary outcome measures studied were
death and changes in CD4 cell counts and plasma HIV-1 RNA
concentrations.
The patients, recruited from 33 AIDS Clinical Trials Units and
7 National Hemophilia Foundation sites in the United States and
Puerto Rico (see the Appendix), had to be more than 16 years
old and had to have laboratory documentation of HIV-1 infec-
tion, a CD4 cell count of 200 per cubic millimeter or less within
the 60 days before entry into the study, at least 3 months of prior
zidovudine treatment, no more than 1 week of prior lamivudine
treatment, no prior treatment with protease inhibitors, a Karnof-
sky performance score of at least 70, and acceptable laboratory
values. The study was approved by the institutional review boards
of the participating institutions, and all the patients gave written
informed consent.
The patients received open-label zidovudine (200 mg three
times daily) and lamivudine (150 mg two times daily) and were
randomly assigned to receive indinavir (800 mg) or matching pla-
cebo every eight hours. In the first version of the protocol, only
patients who could tolerate zidovudine and who had had at least
6 months of prior zidovudine therapy were enrolled, and the sub-
stitution of stavudine for zidovudine was permitted in the event
of drug-associated toxicity at any point after randomization or if
clinical progression of HIV-1 disease occurred that did not fulfill
the criteria for a protocol-defined AIDS event at or beyond 24
weeks of study. The dose of stavudine was 40 mg two times daily
(or 30 mg two times daily for patients weighing less than 60 kg).
A protocol modification in October 1996 reduced the required
prior exposure to zidovudine to at least three months and permit-
ted patients who could not tolerate zidovudine to enter the study
with stavudine substituted for zidovudine at the time of random-
ization. Prophylaxis for 
 
P. carinii
 
 pneumonia was mandated. Pro-
phylaxis for other opportunistic infections was permitted, al-
though the use of rifabutin was prohibited.
Patients who had verified AIDS-defining events were offered
open-label indinavir therapy with the approval of the study chairs
and without having their initial treatment assignments revealed.
All potential AIDS-defining events were reviewed in a blinded
fashion by the study chair; only those that met the criteria defined
in the study protocol were included in the analysis.
 
Monitoring and Enrollment
 
The patients were followed at weeks 4, 8, and 16 and every
eight weeks thereafter with a clinical assessment and routine lab-
oratory monitoring. CD4 cell counts were determined twice at
base line and at weeks 4, 8, 24, and 40. Enrollment began in Jan-
uary 1996. The study was reviewed twice by a data and safety
monitoring board. At the second such review, on February 18,
1997, the comparison of the groups based on data on the patients
randomized by January 27, 1997, showed a significant difference
between groups that met the prespecified guideline for stopping
the study.
 
28
 
 At that time, the board recommended that the accru-
al of patients be terminated and the study closed.
Plasma HIV-1 RNA concentrations were determined retro-
spectively in appropriately stored specimens from 190 randomly
selected patients. These concentrations were measured twice at
base line and at weeks 4, 8, 24, and 40 (Roche Amplicor HIV-1
Monitor assay).
 
29
 
Statistical Analysis
 
The times to events were compared between treatment groups
by Kaplan–Meier estimates, log-rank tests, and proportional-haz-
ards models stratified according to the CD4 cell count obtained
at the time of screening (50 or fewer vs. 51 to 200 cells per cubic
millimeter).
 
30
 
 Changes in CD4 cell counts over time were com-
pared in a mixed-effects regression model.
 
31
 
 An analysis of covar-
iance adjusted for the screening CD4 cell count and the AIDS
Clinical Trials Unit was used to compare changes in the CD4 cell
count and the HIV-1 RNA concentration at each measurement.
 
32
 
With regard to changes in HIV-1 RNA, this calculation used a
regression for censored data: concentrations below the limit of
quantification, 500 copies per milliliter, were censored.
 
33
 
 Analyses
of all the variables pertaining to efficacy were performed on an
intention-to-treat basis that included data on all patients random-
ized and all available follow-up data (including that obtained after
the discontinuation of the study treatment). In the analyses of ad-
verse events, the treatments were compared by a chi-square test;
the follow-up data were censored either when a patient began re-
ceiving open-label indinavir or 56 days after the permanent dis-
continuation of the study treatment, whichever came first, and
were restricted to patients for whom the study treatment was dis-
pensed. All reported P values are two-sided. P values, estimates of
differences between treatments, and 95 percent confidence inter-
vals are unadjusted for the repeated interim analyses.
 
RESULTS
 
Accrual and Characteristics of the Patients
 
There were 1156 patients randomized between
January 29, 1996, and January 27, 1997. Of these,
439 (38 percent) had 50 CD4 cells or fewer per cu-
bic millimeter and 717 (62 percent) had 51 to 200
CD4 cells per cubic millimeter. The base-line char-
acteristics of the study patients (Table 1) were well
balanced between treatment groups.
 
Duration of Follow-up and Study Treatment
 
The median duration of follow-up was 38 weeks.
Five percent of the patients were lost to follow-up;
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the duration of follow-up and the percentage of pa-
tients lost to follow-up were similar in both treat-
ment groups and both CD4-cell strata.
Ten patients did not have any study treatment. Of
the remaining 1146 patients, 227 (20 percent) dis-
continued the study treatment prematurely, more
than seven days before reaching a study end point.
The proportion who discontinued the study treat-
ment was higher in the group receiving zidovudine
(or stavudine) and lamivudine (28 percent) than in
the group receiving indinavir, zidovudine (or stavu-
dine), and lamivudine (12 percent, P
 

 
0.001). In
the stratum with 50 CD4 cells or fewer per cubic
millimeter, the proportions of patients discontinuing
the study treatment in the two groups were 32 per-
cent and 16 percent, respectively (P
 

 
0.001), and
in the stratum with 51 to 200 CD4 cells per cubic
millimeter, these proportions were 26 percent and
9 percent (P
 

 
0.001). Only 4 percent of patients
(10 of 227) discontinued the study treatment pre-
maturely because of protocol-defined adverse events:
4 patients assigned to zidovudine (or stavudine) and
lamivudine and 6 patients assigned to indinavir, zi-
dovudine (or stavudine), and lamivudine. Among the
premature discontinuations, 52 percent (117 of 227)
were initiated by the patients, and for approximately
half these patients the reasons given included a de-
sire to seek open-label therapy with protease inhibi-
tors, concern about the plasma HIV-1 RNA concen-
tration (on the basis of determinations made outside
the study), or both.
 
Progression of Disease
 
Ninety-six patients (8 percent) had AIDS-defining
events or died (Table 2). Sixty-three patients (11
percent) assigned to zidovudine (or stavudine) and
lamivudine had disease progression, as compared
with 33 patients (6 percent) assigned to indinavir, zi-
dovudine (or stavudine), and lamivudine (P
 

 
0.001;
estimated hazard ratio, 0.50; 95 percent confidence
interval, 0.33 to 0.76) (Fig. 1A). There was no sig-
nificant difference in the relative effects of the two
treatments between the patients with 50 CD4 cells
or fewer per cubic millimeter and the patients with
51 to 200 CD4 cells per cubic millimeter. Forty-four
patients in the former stratum (20 percent) had
AIDS-defining events or died in the group assigned
to zidovudine (or stavudine) and lamivudine, as
compared with 23 patients (11 percent) in the
group assigned to indinavir, zidovudine (or stavu-
dine), and lamivudine (P
 

 
0.005; estimated hazard
ratio, 0.49; 95 percent confidence interval, 0.30 to
0.82) (Fig. 1B). In the stratum with 51 to 200 CD4
cells per cubic millimeter, 19 patients (5 percent)
had AIDS-defining events or died in the group as-
signed to zidovudine (or stavudine) and lamivudine,
as compared with 10 patients (3 percent) in the
group assigned to indinavir, zidovudine (or stavu-
 
*Plus–minus values are means 
 

 
SD. Because of rounding, not all columns total 100 percent.
†Values shown are the means of two measurements obtained at least one day apart. Values obtained
at screening, which had to be 
 

 
200 cells per cubic millimeter, were not included in this calculation.
‡HIV-1 RNA was measured in a randomly selected cohort of 190 patients (75 patients with 50
CD4 cells or fewer per cubic millimeter and 115 patients with 51 to 200 CD4 cells per cubic milli-
meter).
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OUNT
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 C
 
UBIC
 
 M
 
ILLIMETER
 

 
50 
 
CELLS
 
(
 
N
 

 
439)
51–200 
 
CELLS
 
(
 
N
 

 
717)
Male sex — no. (%) 956 (83) 365 (83) 591 (82)
Age — yr 39
 

 
9 39
 

 
8 40
 

 
9
Race or ethnic group — no. (%)
White, non-Hispanic
African American
Hispanic
Asian Pacific or other
598 (52)
328 (28)
205 (18)
25 (2)
203 (46)
142 (32)
84 (19)
10 (2)
395 (55)
186 (26)
121 (17)
15 (2)
Injection-drug use — no. (%)
Hemophilia — no. (%)
184 (16)
36 (3)
67 (15)
16 (4)
117 (16)
20 (3)
Karnofsky score 
 

 
90 — no. (%) 942 (81) 317 (72) 625 (87)
CD4 count — cells/mm
 
3
 
† 87
 

 
70 22
 

 
24 126
 

 
59
HIV-1 RNA — log
 
10
 
 copies/ml‡ 5.0
 

 
0.6 5.2
 

 
0.5 4.9
 

 
0.7
Months of prior zidovudine therapy, 
alone or in combination — median 
(25th, 75th percentile)
21 (10, 42) 19 (10, 36) 22 (10, 48)
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dine), and lamivudine (P
 
0.08; estimated hazard
ratio, 0.51; 95 percent confidence interval, 0.24 to
1.10) (Fig. 1C).
Overall, 26 patients died (2.2 percent) (Table 2).
Eighteen patients (3.1 percent) died in the group as-
signed to zidovudine (or stavudine) and lamivudine,
as compared with eight (1.4 percent) in the group
assigned to indinavir, zidovudine (or stavudine), and
lamivudine (P0.04; estimated hazard ratio, 0.43;
95 percent confidence interval, 0.19 to 0.99). There
was no significant difference in the relative effects of
the two treatments between the two strata. Among
the patients with 50 CD4 cells or fewer per cubic
millimeter, 13 patients receiving only the two nucle-
oside analogues died (5.9 percent), as compared
with 5 patients receiving all three drugs (2.3 percent;
P0.05; estimated hazard ratio, 0.37; 95 percent
confidence interval, 0.13 to 1.04). Among the pa-
tients with 51 to 200 CD4 cells per cubic millimeter,
five patients assigned to zidovudine (or stavudine)
and lamivudine (1.4 percent) died, as compared with
three patients assigned to indinavir, zidovudine (or
stavudine), and lamivudine (0.8 percent).
A total of 109 of the 1156 patients (9.4 percent)
were treated with stavudine instead of zidovudine
before the development of an AIDS-defining event
or death. None of the three patients who were ini-
tially assigned to stavudine had a protocol-defined
end point. Among the 106 patients in whom stavu-
dine was substituted for zidovudine after random-
ization, 3 (all in the two-nucleoside group) had
AIDS-defining events, and none died.
AIDS-Defining Events
In all, there were 91 AIDS-defining events (in-
cluding multiple events per patient). Sixty of these
occurred among the patients assigned to receive zi-
dovudine (or stavudine) and lamivudine, as com-
pared with 31 among the patients assigned to indin-
avir, zidovudine (or stavudine), and lamivudine. The
most common events were infections with P. carinii,
cytomegalovirus, and Mycobacterium avium com-
plex (constituting 25 percent, 20 percent, and 16
percent of events, respectively).
Changes in CD4 Cell Counts
Increased CD4 cell counts that persisted above
base-line values were seen in both treatment groups,
with superior responses in the group receiving indin-
avir. At weeks 4, 8, 24, and 40, the mean CD4 cell
count in the patients assigned to zidovudine (or stav-
udine) and lamivudine increased by 27, 30, 18, and
40 cells per cubic millimeter, respectively. The corre-
sponding mean increases in the patients assigned to
indinavir, zidovudine (or stavudine), and lamivudine
were 46, 65, 91, and 121 cells per cubic millimeter
(Fig. 2A). Thus, the change at week 4 was greater by
19 cells per cubic millimeter (P0.001) in the group
that received indinavir, and the difference increased
with time (P0.001), to 36, 73, and 82 cells per cu-
bic millimeter at weeks 8, 24, and 40, respectively.
The responses of the CD4 cell count to treatment
are shown in Figures 2B and 2C. In the group re-
ceiving zidovudine (or stavudine) and lamivudine,
the early increases from base line — those at weeks
4 and 8 — were smaller in the stratum with 50 CD4
cells or fewer per cubic millimeter than in the stra-
tum with 51 to 200 CD4 cells per cubic millimeter.
However, the changes from base line in the longer
term — those at weeks 24 and 40 — were similar in
the two strata. Exploratory analyses of the CD4 cell
counts in the two treatment groups when the data
were censored at the times patients changed from
the treatment to which they were initially assigned
showed increases from base line that were similar to
those in the intention-to-treat analyses at weeks 4,
*The reference group is the group receiving zidovudine (or stavudine) and lamivudine.
†Values were calculated by the log-rank test.
TABLE 2. RATES OF DISEASE PROGRESSION ACCORDING TO CD4 CELL COUNT
AT THE TIME OF SCREENING.
VARIABLE
INDINAVIR, ZIDOVUDINE 
(OR STAVUDINE),
AND LAMIVUDINE
ZIDOVUDINE 
(OR STAVUDINE)
AND LAMIVUDINE
HAZARD RATIO
(95% CONFIDENCE 
INTERVAL)* P VALUE†
no. of patients (%)
All patients
AIDS or death
Death
577
33 (6)
8 (1)
579 
63 (11)
18 (3)
0.50 (0.33–0.76)
0.43 (0.19–0.99)
0.001
0.04
50 CD4 cells/mm3
AIDS or death
Death
219 
23 (11)
5 (2)
220 
44 (20)
13 (6)
0.49 (0.30–0.82)
0.37 (0.13–1.04)
0.005
0.05
51–200 CD4 cells/mm3
AIDS or death
Death
358
10 (3)
3 (1)
359 
19 (5)
5 (1)
0.51 (0.24–1.10)
0.59 (0.14–2.46)
0.08
0.46
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8, and 24 (data not shown). At week 40, the differ-
ence between the two treatment groups was smaller
in the intention-to-treat analysis than in the cen-
sored analysis (difference in mean change, 82 vs. 115
cells per cubic millimeter), suggesting that the dif-
ference may have been reduced by the greater pro-
portion of subjects who changed treatment in the
group receiving zidovudine (or stavudine) and lami-
vudine.
Changes in Plasma HIV-1 RNA Concentrations
The responses of the plasma HIV-1 RNA concen-
trations to treatment were studied in 190 randomly
selected patients. There were persistent decreases
from the base-line values in both treatment groups,
with significantly better responses in the group
whose treatment included indinavir (P0.001 in an
area-under-the-curve analysis). At weeks 4, 8, 24,
and 40, the mean decreases in plasma HIV-1 RNA
Figure 1. Kaplan–Meier Estimates of the Proportion of Patients
Who Did Not Reach the Primary Study End Point of AIDS or
Death.
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in the group receiving zidovudine (or stavudine) and
lamivudine were 0.9, 0.6, 0.6, and 1.0 log10 copies
per milliliter, respectively. The corresponding de-
creases in the group receiving indinavir, zidovudine
(or stavudine), and lamivudine were 1.8, 2.3, 2.8,
and 2.1 log10 copies per milliliter (Fig. 3A). The
changes from base line were significantly greater at
each time point in the group treated with indinavir
(P0.001 at weeks 4, 8, and 24; P0.007 at week
40). At week 24, the proportion of patients with
plasma HIV-1 RNA concentrations of less than 500
copies per milliliter was 9 percent in the two-nucle-
oside group, as compared with 60 percent in the
group treated with indinavir.
The plasma HIV-1 RNA responses according to
the CD4 cell count are shown in Figures 3B and 3C.
In the patients with 50 CD4 cells or fewer per cubic
millimeter, the decreases in plasma HIV-1 RNA ap-
peared to be smaller than those in the patients with
51 to 200 CD4 cells per cubic millimeter. However,
conclusions about stratum-specific plasma HIV-1
RNA responses need to be made cautiously because
of the small numbers of patients followed through
week 40.
Adverse Events
The proportion of patients with signs and symp-
toms that were severe (grade 3) or worse (grade 4)
in the group receiving zidovudine (or stavudine) and
lamivudine was 18 percent, as compared with 21
percent in the group receiving indinavir, zidovudine
(or stavudine), and lamivudine (P0.17). The most
common symptoms were nonspecific discomfort,
malaise, fever, headache, and nausea and vomiting,
with no difference in the reporting of symptoms be-
tween treatment groups.
The proportion of patients with severe laboratory
abnormalities or worse in the group receiving zido-
vudine (or stavudine) and lamivudine was 26 per-
cent, as compared with 21 percent in the group
receiving indinavir, zidovudine (or stavudine), and
lamivudine (P0.06). This difference primarily re-
flected a difference between the groups in the inci-
dence of neutropenia (15 percent and 5 percent, re-
spectively; P0.001). In contrast, the proportion of
patients with hyperbilirubinemia was 1 percent in
the two-nucleoside group, as compared with 6 per-
cent in the group treated with indinavir (P0.001),
a finding compatible with the known elevation of in-
direct bilirubin associated with the use of indinavir.
Two percent of the patients in each treatment group
had hyperglycemia.
Five patients receiving zidovudine (or stavudine)
and lamivudine (1 percent) had episodes of renal
colic or nephrolithiasis (irrespective of grade), as
compared with 21 patients receiving indinavir, zido-
vudine (or stavudine), and lamivudine (4 percent,
P0.001). Three of the five patients in the two-
Figure 3. Mean Change from Base Line in the Plasma HIV-1
RNA Concentration.
For this analysis, 190 patients were randomly selected and
their HIV-1 RNA concentrations were studied. The number of
patients who could be evaluated at each time point is shown.
Bars indicate 95 percent confidence intervals.
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nucleoside group in whom renal colic or nephro-
lithiasis developed had that condition after discon-
tinuing the study treatment and starting open-label
indinavir treatment.
Five new diagnoses of diabetes mellitus were re-
corded: two in the two-nucleoside group and three
in the group treated with indinavir.
DISCUSSION
This study showed the clinical superiority of the
three-drug regimen containing indinavir over the
two-nucleoside combination in patients previously
treated with zidovudine who had CD4 cell counts
of 200 per cubic millimeter or less. The proportion
of patients whose disease progressed to AIDS or
death was reduced from 11 percent to 6 percent by
the three-drug combination, a 50 percent reduction
(P0.001). The hazard ratios in the study patients
as a whole (0.50), those with CD4 cell counts of 50
per cubic millimeter or less (0.49), and those with
counts of 51 to 200 per cubic millimeter (0.51)
were very similar, suggesting that the effect of treat-
ment was similar across the study population, al-
though the possibility of differential effects cannot
be ruled out. Mortality, low in both groups, was re-
duced from 3.1 percent to 1.4 percent with the
three-drug regimen (P0.04). Thus, there was evi-
dence of a reduction in mortality that was consistent
with the reduced risk of progression to the primary
outcome measure of AIDS or death.
The rate of loss to follow-up in this study was low
(5 percent), and the overall rate of premature dis-
continuation of treatment was moderate (20 per-
cent). Seventy-nine percent of the 96 AIDS-defining
events or deaths occurred while the patients were re-
ceiving the study treatment or within seven days of
its discontinuation. Although rates of withdrawal from
treatment differed between the two study groups, the
tendency for patients who withdrew prematurely
from the two-nucleoside group to seek treatment
with protease inhibitors would tend to narrow the
differences between the groups in rates of disease
progression and therefore should not affect the con-
clusions of the study. Conversely, when a study is ter-
minated early because a stopping guideline is used,
differences between the treatment groups tend to be
overestimated because of random variation.34 How-
ever, it is impossible to determine the relative mag-
nitude of these effects.
These findings confirm on the basis of clinical end
points the results of earlier trials of the combination
of indinavir, zidovudine, and lamivudine in patients
previously treated with zidovudine, trials that showed
that the three-drug combination produces superior
responses in plasma HIV-1 RNA concentrations and
CD4 cell counts.24,25 The suppression of plasma
HIV-1 RNA to unquantifiable levels in the majority
of subjects with this drug combination is accompa-
nied by greater suppression of HIV-1 RNA expres-
sion in lymphoid tissue35 and may prevent the emer-
gence of resistance — factors that may add to the
clinical benefit now established for this regimen.
Our study also found superior responses of CD4
cells and plasma HIV-1 RNA with the three-drug
regimen.
We chose the combination of zidovudine and la-
mivudine as the control treatment because of the
unique interactions between these two agents with
respect to mutations conferring resistance, the re-
sults of phase 2 trials, the tolerance associated with
the regimen, and its widespread use in clinical prac-
tice.36-40 The clinical benefit of lamivudine when that
drug is added to previously available nucleoside an-
alogues to treat patients with 25 to 250 CD4 cells
per cubic millimeter was recently confirmed in the
CAESAR trial, in which the risk of AIDS or death
was reduced by approximately 50 percent.41 In the
control group in our study, there was a relatively low
rate of disease progression, as well as a moderate
increase in the CD4 cell count and a decline in plas-
ma HIV-1 RNA; these persisted throughout the
study, even though it is now recognized that simply
adding lamivudine to a preexisting regimen is not a
standard clinical approach. The strength of the con-
trol group in this study is also an important differ-
ence between this study and previously reported
studies of other HIV-protease inhibitors that have
assessed clinical end points.42,43 In the Abbott M94-
247 trial, ritonavir or placebo was added to stable
prior nucleoside-analogue therapy or no therapy.42
In the Hoffmann–La Roche NV14256 trial, a regi-
men of saquinavir plus zalcitabine was compared with
zalcitabine monotherapy.43 In the context of these
other trials, our study makes it clear that more po-
tent therapies, now represented by three-drug regi-
mens containing a protease inhibitor, are preferable
in patients with advanced disease. The durability of
the clinical benefit conferred by indinavir as part of
a three-drug regimen has not been fully defined,
however.
Improving the use of the currently approved agents
to treat HIV-1 infection, and the promising drugs
on the clinical horizon,44-46 in the management of
HIV-1 disease remains a challenge.47 However, this
study supports the view that employing well-tolerat-
ed regimens of increasing potency will translate into
greater clinical benefits for patients with HIV-1 in-
fection.
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APPENDIX
The following institutions and investigators participated in the AIDS
Clinical Trials Group 320 Study: University of North Carolina — T. Lane
and J. Horton; University of Cincinnati — D. Neumann and B. Letcher;
University of Puerto Rico — G. Vazquez, M. Cruz-Ortiz, and I. Lopes;
University of Minnesota — C. Kumekawa, R. Schut, and S. Swindells; Wash-
ington University — P. Tebas, W. Powderly, and A. Slack; Ohio State Uni-
versity College of Medicine — M. Para, R. Fass, and J. Neidig; Northwestern
University — J. Pulvirenti and J. Pottage, Jr.; University of Alabama and
Emory University — J. Lennox and K. Tamburello; New York University
Medical Center and Bellevue Hospital — R. Gulick, J. Dowling, and M. La-
verty; University of Miami — E. Scerpella and A. Rodriguez; University of
Texas at Galveston — R. Pollard, S. Hausrath, and M. Pickthall; Case West-
ern Reserve University — B. Gripshover, H. Valdez, and M. Chance;
Howard University — R. Delapenha, J. McNeil, and Y. Butler; Harvard
University and Boston Medical Center — L. Jackson-Pope and T. Cooley;
University of Rochester — R. Hewitt and C. Greisberger; University of Cal-
ifornia, Los Angeles — R. Mitsuyasu, M. Guerrero, and P. Miller; Indiana
University Hospital — K. Fife, H. Nixon, and D. Heise; Meharry Medical
College and Vanderbilt University Medical Center — M.A. South, D. Haas,
and S. Raffanti; Duke University — C. Hicks, P. Robinson, and K. Shipp;
University of California, San Diego — C. Fegan, T.-C. Meng, and S. Little;
Johns Hopkins University — R. Becker, M. Higgins, L. Apuzzo, and J.B.
Jackson; Mount Sinai Medical Center — P. Gerits, H. Mendoza, and
D. Mildvan; University of Pennsylvania — R.R. MacGregor, I. Matozzo,
and E. McCann; University of Southern California — M. Dube and C. Ol-
sen; University of Colorado — D. Kuritzkes, B. Putnam, and D. Torre; Tu-
lane University and Louisiana State University — J. Lertora, R. Clark, and
M. Beilke; University of Hawaii — S. Souza, M. Millard, and L. Oshita;
Stanford University — T. Merigan, Jr., J. Fessel, and D. Israelski; Memorial
Sloan-Kettering Cancer Center — M. Giordano, P. Ristau, and
M. Granville; University of Washington, Seattle — A. Collier, R. Vasquez,
B. Royer, and R. Coombs; New York University Medical Center and Belle-
vue Hospital (pediatric site) — W. Borkowsky, S. Chandwani, and M. Mint-
er; Columbus Children’s Hospital — M. Brady, J. Hunkler, and C. Callaway;
Medical University of South Carolina — G. Johnson and E. Matters; Na-
tional Hemophilia Foundation — T. Coates, T. Hofstra, W.-Y. Wong,
E. Eyster, S. Seremetis, C. Kessler, S. Stabler, W. Hanna, C. Leissenger,
J. Gill, P. Timmons, W.K. Hoots, and M. Cantini; Division of AIDS, Na-
tional Institute of Allergy and Infectious Diseases — J. Ioannidis and A. Mar-
tinez; Statistical and Data Management Center — K. Kazial; Harvard
School of Public Health — S.-H. Liou; Community Constituency Group —
H. Chang; Bristol-Myers Squibb — J. Skovronski and L. Dunkle; Merck and
Co. — A. Meibohm.
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